Human BioSciences
Private Company
Total funding raised: $1.2M
Overview
Human BioSciences is a long-established, privately-held player in the advanced wound care market, founded in 1999 and headquartered in Gaithersburg, MD. Its competitive edge is built on the Kollagen™ platform, which utilizes 100% native, non-hydrolyzed Type I collagen to promote faster healing. The company has a commercial portfolio of FDA-cleared medical devices, generates revenue through product sales and contract services, and operates globally with a focus on both human and veterinary medicine. HBS positions itself as a manufacturing and innovation partner, offering OEM and private label capabilities to other companies.
Technology Platform
Kollagen™ Technology: Proprietary platform using 100% native, non-hydrolyzed Type I collagen with preserved triple-helical structure, engineered for bioactivity and stability across all phases of wound healing.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
HBS competes in the crowded advanced wound care market against major players like Smith & Nephew, Mölnlycke, ConvaTec, and 3M, as well as other collagen-focused companies (e.g., Integra LifeSciences, Collagen Solutions). Its differentiation is based on its native collagen technology and its dual role as a product company and a contract development/manufacturing organization (CDMO).